Image

Fruquintinib Combined With TAS-102 in Refractory Metastatic Colorectal Cancer

Fruquintinib Combined With TAS-102 in Refractory Metastatic Colorectal Cancer

Recruiting
18-75 years
All
Phase N/A
  • Technical (Original)
  • Simplified (AI rewritten)

Powered by AI

Overview

Fruquintinib, as a standard treatment for refractory metastatic colorectal cancer (mCRC), has attracted increasing research efforts to explore its innovative strategies in combination with immunotherapy and chemotherapy because of its multi-target mechanism which enhances the sensitivity of the immune system and chemotherapy, aiming to further improve the survival benefits for mCRC patients. Trifluridine/tipiracil (TAS-102) is also a standard treatment for mCRC. This study aims to investigate the safety and effectiveness of the combined use of these two drugs in mCRC.

Eligibility

Inclusion Criteria:

  • Histology-confirmed metastatic CRC (mCRC)
  • Disease progression on standard therapy with at least two lines of chemotherapy, including fluorouracil, oxaliplatin, and irinotecan with or without biologics such as bevacizumab and cetuximab
  • Fruquintinib administered as salvage treatment
  • Age: 18-75 years old
  • Informed consent

Exclusion Criteria:

  • Liver or kidney dysfunction, or other conditions unsuitable for chemotherapy
  • Fruquintinib and/or TAS-102 administration as second-line treatment
  • Drug administration stopped after less than two cycles

Study details
    Colorectal Cancer
    Metastatic Colorectal Cancer
    Refractory Colorectal Carcinoma

NCT06221423

Fudan University

29 January 2024

Contact a study center
Step 1 Get in touch with the nearest study center
We have submitted the contact information you provided to the research team at {{SITE_NAME}}. A copy of the message has been sent to your email for your records.
Would you like to be notified about other trials? Sign up for Patient Notification Services.
Sign up

Send a message

Enter your contact details to connect with study team

Investigator Avatar

Primary Contact

  Other languages supported:

First name*
Last name*
Email*
Phone number*
Other language

FAQs

Learn more about clinical trials

What is a clinical trial?

A clinical trial is a study designed to test specific interventions or treatments' effectiveness and safety, paving the way for new, innovative healthcare solutions.

Why should I take part in a clinical trial?

Participating in a clinical trial provides early access to potentially effective treatments and directly contributes to the healthcare advancements that benefit us all.

How long does a clinical trial take place?

The duration of clinical trials varies. Some trials last weeks, some years, depending on the phase and intention of the trial.

Do I get compensated for taking part in clinical trials?

Compensation varies per trial. Some offer payment or reimbursement for time and travel, while others may not.

How safe are clinical trials?

Clinical trials follow strict ethical guidelines and protocols to safeguard participants' health. They are closely monitored and safety reviewed regularly.
Add a private note
  • abc Select a piece of text.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.